The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Rational design of cationic lipids for siRNA delivery
Abstract
We adopted a rational approach to design cationic lipids for use in formulations to deliver small interfering RNA (siRNA). Starting with the ionizable cationic lipid 1,2-dilinoleyloxy-3-dimethylaminopropane (DLinDMA), a key lipid component of stable nucleic acid lipid particles (SNALP) as a benchmark, we used the proposed in vivo mechanism of action of ionizable cationic lipids to guide the design of DLinDMA-based lipids with superior delivery capacity. The best-performing lipid recovered after screening (DLin-KC2-DMA) was formulated and characterized in SNALP and demonstrated to have in vivo activity at siRNA doses as low as 0.01 mg/kg in rodents and 0.1 mg/kg in nonhuman primates. To our knowledge, this represents a substantial improvement over previous reports of in vivo endogenous hepatic gene silencing.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are limited published data on the in vivo delivery of self-amplifying RNA using nonviral delivery strategies (3,14,18), and none has taken advantage of the recently developed, clinically suitable delivery systems for siRNA (19,20).”
From Nonviral delivery of self-amplifying RNA vaccines (2012) · cites this paper as [19]
In the citing paper
“Recently, there has been an exponential growth in the development of clinically suitable nonviral delivery systems for siRNA (19,20); we have taken advantage of these innovations to develop the LNP/RNA formulation and have now embarked on a more extensive evaluation of other nonviral delivery systems.”
From Nonviral delivery of self-amplifying RNA vaccines (2012) · cites this paper as [19]
In the citing paper
“They can also increase the transport efficiency of siRNA by lowering toxicity and enhancing biological dispersion.319”
From Smart nanoparticles for cancer therapy (2023) · cites this paper as [319]
In the citing paper
“considerable effort has been made to reduce the siRNA payload by developing different lipid formulations for delivery, which has so far led to a tenfold or even 100-fold reduction in the dose of siRNA administered to different models77,78.”
From Perspectives and opportunities for nanomedicine in the management of atherosclerosis (2011) · cites this paper as [77]
In the citing paper
“Semple et al. reported that DLin-KC2-DMA containing stable nucleic acid lipid particles (SNALPs) exhibited in vivo activity at siRNA doses of 0.01 mg/kg in the mouse model and was capable of silencing the TTR gene in nonhuman primates with ED50 around 0.3 mg/kg.[63]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [63]
Citations
Cites
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
RNAi-mediated gene silencing in non-human primates
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., et al. (2006) · Nature · doi:10.1038/nature04688 · Cited by 1,357
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,260
Self-citationPotent and persistent in vivo anti-HBV activity of chemically modified siRNAs
Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K. S., Jensen, K., Breen, W., Hartsough, K. C., Machemer, L., Radka, S. F., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,175
Self-citationA combinatorial library of lipid-like materials for delivery of RNAi therapeutics
Akinc, A., Zumbuehl, A., Goldberg, M., Leshchiner, E. S., Busini, V., Hossain, N., Bacallado, S. A., Nguyen, D. N., Fuller, J., Alvarez, R., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1402 · Cited by 1,150
Self-citationMechanism of DNA Release from Cationic Liposome/DNA Complexes Used in Cell Transfection,
Xu, Y., & Szoka, F. C. (1996) · Biochemistry · doi:10.1021/bi9602019 · Cited by 1,136
Frank-Kamenetsky, M. D., Grefhorst, A., Anderson, N. N., Racie, T., Bramlage, B., Akinc, A., Butler, D., Charissé, K., Dorkin, J. R., Fan, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805434105 · Cited by 644
Self-citationMechanism of oligonucleotide release from cationic liposomes.
Zelphati, O., & Szoka, F. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11493 · Cited by 634
On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids
Hafez, I., Maurer, N., & Cullis, P. R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301506 · Cited by 601
Self-citationCationic lipid saturation influences intracellular delivery of encapsulated nucleic acids
Heyes, J., Palmer, L., Bremner, K., & MacLachlan, I. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.06.014 · Cited by 572
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 1,003
Property-Driven Design and Development of Lipids for Efficient Delivery of siRNA
Rajappan, K., Tanis, S. P., Mukthavaram, R., Roberts, S., Nguyen, M., Tachikawa, K., Sagi, A., Sablad, M., Limphong, P., Leu, A. I., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01407 · Cited by 38
Non-viral siRNA delivery to T cells: Challenges and opportunities in cancer immunotherapy
Hoeck, J. V., Braeckmans, K., Smedt, S. C. D., & Raemdonck, K. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121510 · Cited by 37
Byrnes, A. E., Dominguez, S. L., Yen, C.-W., Laufer, B. I., Foreman, O., Reichelt, M., Lin, H., Sagolla, M., Hötzel, K., Ngu, H., et al. (2023) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2023.05.005 · Cited by 38
Liang, Y., Zhang, J., Xu, C., Wang, J., Han, W., Yang, J., Wu, S., An, J., Liu, J., Zhang, Z., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c04116 · Cited by 36
Kirtane, A. R., Bi, J., Rajesh, N. U., Tang, C., Jiménez, M., Witt, E., McGovern, M. K., Cafi, A. B., Hatfield, S. J., Rosenstock, L., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01360-5 · Cited by 38
Seth, P. P., Allerson, C. R., Siwkowski, A. M., Vasquez, G., Berdeja, A., Migawa, M. T., Gaus, H. J., Prakash, T. P., Bhat, B., & Swayze, E. E. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101207e · Cited by 36
Development of a multifunctional envelope-type nano device and its application to nanomedicine
Sato, Y., Nakamura, T., Yamada, Y., & Harashima, H. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.042 · Cited by 37
Amphiphilic Polypeptides for VEGF siRNA Delivery into Retinal Epithelial Cells
Osipova, O., Sharoyko, V. V., Zashikhina, N., Захарова, Н. В., Tennikova, T. B., Urtti, A. O., & Korzhikova‐Vlakh, E. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12010039 · Cited by 36
“Currently, the encapsulation of the siRNAs into nanoparticles is based on lipids [10,11] or polymers [12,13], or their complexation with cell-penetrating peptides [14,15] or cationic-polymers [16–19].”
BackgroundNonionic Surfactant Vesicles for Delivery of RNAi Therapeutics
Paecharoenchai, O., Teng, L., Yung, B. C., Teng, L., Opanasopit, P., & Lee, R. J. (2013) · Nanomedicine · doi:10.2217/nnm.13.155 · Cited by 36
Li, L., Wang, R., Wilcox, D. M., Sarthy, A. V., Lin, X., Huang, X., Tian, L., Dande, P., Hubbard, R. D., Hansen, T. M., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0983-t · Cited by 36
Zhang, J., Pei, Y., Zhang, H., Wang, L., Arrington, L., Zhang, Y., Glass, A., & Leone, A. M. (2012) · Molecular Pharmaceutics · doi:10.1021/mp3005337 · Cited by 36
Shi, K., Zhao, Y. D., Miao, L., Satterlee, A., Haynes, M. T., Luo, C., Musetti, S., & Huang, L. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.02.008 · Cited by 36
“By interacting with proteoglycans and negatively charged proteins on the cell surface, they often inducing membrane destabilization and non-specific cell necrosis.(25) Therefore, complex with negative nucleic acid or”
BackgroundA decade of the liposome-protein corona: Lessons learned and future breakthroughs in theranostics
Quagliarini, E., Digiacomo, L., Renzi, S., Pozzi, D., & Caracciolo, G. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101657 · Cited by 36
Pratsinis, A., Fan, Y., Portmann, M., Hammel, M., Kou, P., Sarode, A., Ringler, P., Kováčik, Ľ., Lauer, M. E., Lamerz, J., et al. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122874 · Cited by 35
Oligonucleotide delivery: a patent review (2010 – 2013)
Grijalvo, S., Aviñó, A. M., & Eritja, R. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.915944 · Cited by 35
“Although there are some limitations associated to their use, such as low transfection efficiencies, toxicity and stability in the presence of serum [22], to date, the design and synthesis of novel cationic lipid libraries and lipid-like molecules has”
BackgroundNon-viral nucleic acid containing nanoparticles as cancer therapeutics
Kozielski, K., Rui, Y., & Green, J. J. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1190707 · Cited by 35
“mates.[96] Interestingly, some groups have been able to take”
BackgroundsiRNA delivery for treatment of degenerative diseases, new hopes and challenges
Zahir‐Jouzdani, F., Mottaghitalab, F., Dinarvand, M., & Atyabi, F. (2018) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2018.04.001 · Cited by 38
Jiang, Z., Cui, W., Prasad, P., Touve, M. A., Gianneschi, N. C., Mager, J., & Thayumanavan, S. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b01321 · Cited by 36
Pulmonary delivery of mucosal nanovaccines
Tang, W., Zhang, Y., & Zhu, G. (2021) · Nanoscale · doi:10.1039/d1nr06512b · Cited by 40
Development of amino acid-modified biodegradable lipid nanoparticles for siRNA delivery
Patel, P., Fetse, J., Lin, C., Guo, Y., Hasan, M. R., Nakhjiri, M., Zhao, Z., Jain, A., & Cheng, K. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.09.065 · Cited by 37
Recombinant High Density Lipoprotein Nanoparticles for Target-Specific Delivery of siRNA
Rui, M., Tang, H., Li, Y., Wei, X., & Xu, Y. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0957-4 · Cited by 35
“studies revealed that the accumulation of siRNA in the liver was mainly due to the phagocytic activity of the RES(3,5,6).”
InfluentialMontenegro, J., Bang, E., Sakai, N., & Matile, S. (2012) · Chemistry - A European Journal · doi:10.1002/chem.201200550 · Cited by 35
Recent Patents in Cationic Lipid Carriers for Delivery of Nucleic Acids
Koynova, R. D., & Tenchov, B. G. (2011) · Recent Patents on DNA & Gene Sequences · doi:10.2174/187221511794839255 · Cited by 35
What Drives Innovation: The Canadian Touch on Liposomal Therapeutics
Leung, A. W. Y., Amador, C., Wang, L., Mody, U. V., & Bally, M. B. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11030124 · Cited by 38
“These works were further developed in the 1990s and 2000s through the Cullis group (UBC) and Vancouver-based companies, including Acuitas Therapeutics (formerly AlCana Technologies) and Inex Pharmaceuticals (now Arbutus Biopharma) [64,114].”
BackgroundDevelopment of nucleic acid medicines based on chemical technology
Kawamoto, Y., Wu, Y., Takahashi, Y., & Takakura, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114872 · Cited by 34
Brief Comparison of the Efficacy of Cationic and Anionic Liposomes as Nonviral Delivery Systems
Ochoa-Sánchez, C., Rodríguez-León, E., Iñiguez-Palomares, R. A., & Rodríguez-Beas, C. (2024) · ACS Omega · doi:10.1021/acsomega.4c06714 · Cited by 35
Engineering Lipid Nanoparticles for mRNA Immunotherapy
Zwolsman, R. C., Darwish, Y. B., Kluza, E., & van der Meel, R. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70007 · Cited by 37
Zhao, Y., Tian, Z., Wang, J., Cui, M., Cao, Z., Liu, P., Li, R., Cai, S., Hu, Y., Ma, Y., et al. (2025) · Science Advances · doi:10.1126/sciadv.ady6460 · Cited by 37
“This finding suggests that PyCB ILs mediate membrane disruption by promoting the transition from a bilayer structure to the inverted hexagonal II phase ( 46 ), which is the same as ALC-0315 ILs.”
Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery
Li, L., Wang, R., Wilcox, D. M., Zhao, X. B., Song, J. C., Li, X., Kohlbrenner, W. M., Fesik, S. W., & Shen, Y. (2011) · Gene Therapy · doi:10.1038/gt.2011.146 · Cited by 34
Noncovalent tagging of siRNA with steroids for transmembrane delivery
Tai, W., & Gao, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.02.007 · Cited by 34
Small Delivery Vehicles of siRNA for Enhanced Cancer Targeting
Kim, H. J., Yi, Y., Kim, A., & Miyata, K. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00546 · Cited by 33
Cationic Nanostructures for Vaccines Design
Carmona‐Ribeiro, A. M., & Pérez-Betancourt, Y. (2020) · Biomimetics · doi:10.3390/biomimetics5030032 · Cited by 33
“Among the approaches used to deliver RNA are those based on non-saturated double-chained cationic lipids [97].”
BackgroundMethodMeng, N., & Grimm, D. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00642-z · Cited by 35
“and Semple et al.(4) c Rationally designed iPhos with one ionizable amine, one phosphate group, and three alkyl tails (x and y indicate the carbon lengths).”
BackgroundLipid-peptide nanocomplexes for mRNA delivery in vitro and in vivo
Grant-Serroukh, D., Hunter, M. R., Maeshima, R., Tagalakis, A. D., Aldossary, A. M., Allahham, N., Williams, G. R., Edbrooke, M. R., Desai, A. S., & Hart, S. L. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.018 · Cited by 37
Kumar, K., Maiti, B., Kondaiah, P., & Bhattacharya, S. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500620e · Cited by 34
Delivery of RNAi therapeutics: work in progress
Miller, A. D. (2013) · Expert Review of Medical Devices · doi:10.1586/17434440.2013.855471 · Cited by 34
Ag@4ATP-coated liposomes: SERS traceable delivery vehicles for living cells
Zhu, D., Wang, Z., Zong, S., Chen, H., Wu, X., Pei, Y., Chen, P., Ma, X., & Cui, Y. (2014) · Nanoscale · doi:10.1039/c4nr00557k · Cited by 34
Gonçalves, N. P., Moreira, J., Martins, D. F., Vieira, P., Obici, L. P., Merlini, G., Saraiva, M., & Saraiva, M. J. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0891-9 · Cited by 35
“TTR or control small interfering RNA (siRNA) (vehicle) were formulated into a lipid nanoparticle delivery system [36].”
MethodRahimi, A., Esmaeili, Y., Dana, N., Dabiri, A., Rahimmanesh, I., Jandaghian, S., Vaseghi, G., Shariati, L., Zarrabi, A., Javanmard, S. H., et al. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106476 · Cited by 36
Enhancing siRNA cancer therapy: Multifaceted strategies with lipid and polymer-based carrier systems
Dastgerdi, N. K., Dastgerdi, N. K., Bayraktutan, H., Costabile, G., Atyabi, F., Dinarvand, R., Longobardi, G., Alexander, C., & Conte, C. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124545 · Cited by 39
Neumann, U. H., Ho, J. S. S., Chen, S., Tam, Y. Y. C., Cullis, P. R., & Kieffer, T. J. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.012 · Cited by 33
Self-citationEngineering lymphocytes with RNAi
Ramishetti, S., & Peer, D. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.12.002 · Cited by 33
Synthetic Vehicles for Encapsulation and Delivery of CRISPR/Cas9 Gene Editing Machinery
Carboni, V., Maaliki, C., Alyami, M., Alsaiari, S. K., & Khashab, N. M. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201800085 · Cited by 34
Li, L., Foley, J. P., & Helmy, R. (2019) · Journal of Chromatography A · doi:10.1016/j.chroma.2019.04.061 · Cited by 33
Environment‐Responsive Lipid/siRNA Nanoparticles for Cancer Therapy
Lu, Z., Laney, V. E. A., Hall, R. C. W., & Ayat, N. R. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202001294 · Cited by 33
Efficient delivery of VEGFA mRNA for promoting wound healing via ionizable lipid nanoparticles
Dong, S., Wang, J., Guo, Z., Zhang, Y., Zha, W., Wang, Y., Liu, C., Xing, H., & Li, X. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.117135 · Cited by 33
Fàbrega, C., Aviñó, A. M., Navarro, N., Jorge, A. F., Grijalvo, S., & Eritja, R. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020320 · Cited by 34
“To expand the arsenal of available cationic lipids for siRNAs delivery, several lipids and lipoids libraries were screened, thereby generating lipids with high efficiency and less toxicity [58,59].”
BackgroundIncorporation of mRNA in Lamellar Lipid Matrices for Parenteral Administration
Ziller, A., Nogueira, S. S., Huehn, E., Funari, S. S., Brezesinski, G., Hartmann, H., Şahin, U., Haas, H., & Langguth, P. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b01022 · Cited by 34
Gallud, A., Munson, M. J., Liu, K., Idström, A., Barriga, H. M. G., Tabaei, S. R., Aliakbarinodehi, N., Ojansivu, M., Lubart, Q., Doutch, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.20.457104 · Cited by 35
He, X., Chang, Z., Chen, F., Zhang, W., Sun, M., Shi, T., Liu, J., Chen, P., Zhang, K., Guan, S., et al. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.10.038 · Cited by 34
Laila, U. E., An, W., & Xu, Z.-X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1448489 · Cited by 34
Delivery of gene silencing agents for breast cancer therapy
Shen, H., Mittal, V., Mauro Ferrari, B., & Chang, J. C. (2013) · Breast Cancer Research · doi:10.1186/bcr3413 · Cited by 32
Kim, H.-K., Thompson, D. H., Jang, H. S., Chung, Y. J., & den Bossche, J. V. (2013) · ACS Applied Materials & Interfaces · doi:10.1021/am400977t · Cited by 32
The development of an in vitro assay to screen lipid based nanoparticles for siRNA delivery
Zhang, Y., Arrington, L., Boardman, D., Davis, J., Xu, Y., DiFelice, K., Stirdivant, S. M., Wang, W., Budzik, B., Bawiec, J., et al. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.11.006 · Cited by 31
Advances in RNAi therapeutic delivery to leukocytes using lipid nanoparticles
Ramishetti, S., Landesman‐Milo, D., & Peer, D. (2016) · Journal of drug targeting · doi:10.3109/1061186x.2016.1172587 · Cited by 32
“Most importantly, the acidic pH in endosomes makes the lipid positive, enabling interaction with endosomal membranes to form non-bilayer structures that result in membrane disruption followed by release of siRNA (Figure 1c) [40,44].”
BackgroundLi, Y., Liu, L., Ji, W., Peng, H., Zhao, R., & Zhang, X. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101006 · Cited by 34
Wang, A. Y. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158148 · Cited by 34
“The positively charged head group controls the association between the lipid and phosphate backbone of the RNA and assists RNA condensation [81,82].”
BackgroundGouda, N. A., Miyata, K., Christie, R. J., Suma, T., Kishimura, A., Fukushima, S., Nomoto, T., Liu, X., Nishiyama, N., & Kataoka, K. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.09.077 · Cited by 33
Roloff, A., Nelles, D. A., Thompson, M. P., Yeo, G. W.-M., & Gianneschi, N. C. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00657 · Cited by 32
Dendritic peptide bolaamphiphiles for siRNA delivery to primary adipocytes
Eldredge, A. C., Johnson, M. E., Cao, Y., Zhang, L., Zhao, C., Liu, Z., Yang, Q., & Guan, Z. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.024 · Cited by 32
Carneiro, S. P., Greco, A., Chiesa, E., Genta, I., & Merkel, O. M. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2185220 · Cited by 33
“5 to 10 mol%) the potency of LNPs improved 5 times [77,86,87].”
BackgroundResponsive Microneedles as a New Platform for Precision Immunotherapy
Liu, X., Song, H., Sun, T., & Wang, H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051407 · Cited by 31
“Hyaluronic acid-based microneedles encapsulating tumor lysates, melanin, and adjuvants Near-infrared B16F10 whole tumor lysate Cancer immunotherapy [119]”
BackgroundDelivery of nucleic acids using nanomaterials
Qin, Y., Ou, L., Zha, L., Zeng, Y., & Li, L. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00160-0 · Cited by 35
“Later, a more potent ionizable lipid 2,2-dilinoleyl-4-dimethylaminoethyl-1,3-dioxolane (DLin-KC2-DMA) was developed [226].”
BackgroundCalculating Apparent p K a Values of Ionizable Lipids in Lipid Nanoparticles
Hamilton, N. B., Arns, S., Shelley, M. Y., Bechis, I., & Shelley, J. C. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00426 · Cited by 30
Vlasova, K. Y., Kerr, A., Pennock, N. D., Jozić, A., Sahel, D. K., Gautam, M., Murthy, N. T. V., Roberts, A., Ali, M. W., MacDonald, K. D., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59136-z · Cited by 35
“Studies suggest an optimal molar content of cholesterol typically in the range of 38.5 – 50% 68,69 , here, we chose 50% of cholesterol, aligned with literature 70 .”
InfluentialRNA Interference-Based Therapeutics: Molecular Platforms for Infectious Diseases
Dyawanapelly, S., Ghodke, S., Vishwanathan, R., Dandekar, P. P., & Jain, R. D. (2014) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2014.1929 · Cited by 31
Barrett, S. E., Burke, R. S., Abrams, M. T., Bason, C., Busuek, M., Carlini, E. J., Carr, B., Crocker, L. S., Fan, H., Garbaccio, R. M., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.028 · Cited by 31
MicroRNAs in Liver Health and Disease
Hsu, S., & Ghoshal, K. (2013) · Current Pathobiology Reports · doi:10.1007/s40139-012-0005-4 · Cited by 32
Sato, Y., Sakurai, Y., Kajimoto, K., Nakamura, T., Yamada, Y., Akita, H., & Harashima, H. (2016) · Macromolecular Bioscience · doi:10.1002/mabi.201600179 · Cited by 32
Zahir‐Jouzdani, F., Soleimani, M., Mahbod, M., Mottaghitalab, F., Vakhshiteh, F., Arefian, E., Shahhoseini, S., Dinarvand, R., & Atyabi, F. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-0546-0 · Cited by 31
Manna, I., & Bandyopadhyay, M. (2018) · Plant Gene · doi:10.1016/j.plgene.2018.100167 · Cited by 33
Biswas, A., Chakraborty, K., Dutta, C., Mukherjee, S., Gayen, P., Jan, S., Mallick, A. M., Bhattacharyya, D., & Roy, R. S. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b13794 · Cited by 31
Kimura, N., Maeki, M., Ishida, A., Tani, H., & Tokeshi, M. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c01519 · Cited by 32
Nakamura, T., Nakade, T., Yamada, K., Sato, Y., & Harashima, H. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121140 · Cited by 31
mRNA-based modalities for infectious disease management
Zhang, M., Hussain, A., Yang, H., Zhang, J., Liang, X., & Huang, Y. (2022) · Nano Research · doi:10.1007/s12274-022-4627-5 · Cited by 35
Designer Lipids Advance Systemic siRNA Delivery
Liu, Y., & Huang, L. (2010) · Molecular Therapy · doi:10.1038/mt.2010.39 · Cited by 31
Vieira, M., Gomes, J. R., & Saraiva, M. J. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8824-4 · Cited by 36
“TTR or control siRNA was formulated into a lipid nanoparticle (LNP) delivery system kindly provided byAlnylam Pharmaceuticals (Boston) [36].”
Kinetics of RNA-LNP delivery and protein expression
Müller, J., Schäffler, N. G., Kellerer, T., Schwake, G., Ligon, T. S., & Rädler, J. O. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114222 · Cited by 35
Chen, Z., Shu, J., Hu, Y., & Mei, H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.09.019 · Cited by 32
Inhalable Dry Powders for Lung mRNA Delivery
Gordon, A. G. R., Li, B., Witten, J. J., Nguyen, H. Q., & Anderson, D. G. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400509 · Cited by 36
Lipid nanoparticles: a promising tool for nucleic acid delivery in cancer immunotherapy
Abaza, T., Mohamed, E., & Zaky, M. Y. (2025) · Medical Oncology · doi:10.1007/s12032-025-02939-3 · Cited by 35
“Therefore, to address these issues, the amount of PEG is kept as low as possible, which, along with elevated ionizable content, has been associated with a reported fivefold improvement in potency [23].”
Ma, H., Dallas, A., Ilves, H., Shorenstein, J., MacLachlan, I., Klumpp, K., & Johnston, B. H. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.09.049 · Cited by 30
Self-citationLiu, Y.-K., Lin, Y., Chen, C., Lin, C., Ma, K., Chou, F.-H., Tsai, J.-S., Lin, H., Chen, F., Cheng, T., et al. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.23048 · Cited by 30
Triggering RNAi with multifunctional RNA nanoparticles and their delivery
Dao, B. N., Viard, M., Martins, A. N., Kasprzak, W. K., Shapiro, B. A., & Afonin, K. A. (2015) · DNA and RNA Nanotechnology · doi:10.1515/rnan-2015-0001 · Cited by 30
“Ionizable lipids establish a positive charge in an acidic environment and can undergo interactions with anionic endosomal lipids [131].”
BackgroundTagalakis, A. D., Maeshima, R., Yu‐Wai‐Man, C., Meng, J., Syed, F., Wu, L., Aldossary, A. M., McCarthy, D., Moghimi, S. M., & Hart, S. L. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.01.048 · Cited by 30
“more popular with the development of small interfering RNA (siRNA)-mediated silencing and 67 chemically-modified mRNA [1-4].”
BackgroundNucleic acid combinations: A new frontier for cancer treatment
Remant Bahadur, K. C., Thapa, B., Valencia‐Serna, J., Aliabadi, H. M., & Uludağ, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.04.029 · Cited by 30
Watching the gorilla and questioning delivery dogma
Anchordoquy, T. J., & Simberg, D. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.07.021 · Cited by 30
“Actually, some of the nanoparticlemediated siRNA formulations showing promise in clinical trials are not long-circulating [33, 34].”
BackgroundStereoselective pH Responsive Peptide Dendrimers for siRNA Transfection
Heitz, M., Javor, S., Darbre, T., & Reymond, J. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00403 · Cited by 30
Structural Properties of Inverted Hexagonal Phase: A Hybrid Computational and Experimental Approach
Ramezanpour, M., Schmidt, M. L., Bashe, B. Y. M., Pruim, J. R., Link, M., Cullis, P. R., Harper, P. E., Thewalt, J. L., & Tieleman, D. P. (2020) · Langmuir · doi:10.1021/acs.langmuir.0c00600 · Cited by 31
Self-citationNanotechnology‐Based CAR‐T Strategies for Improving Efficacy and Safety of Tumor Immunotherapy
Wang, X., Meng, F., Yen, Y., Li, R., & Liu, B. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202004713 · Cited by 33
Opportunities for innovation: Building on the success of lipid nanoparticle vaccines
Huang, J. Y., Yuen, D., Mintern, J. D., & Johnston, A. P. R. (2021) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2021.101468 · Cited by 31
Smart thrombosis inhibitors without bleeding side effects via charge tunable ligand design
La, C. C., Smith, S. A., Vappala, S., Adili, R., Luke, C. E., Abbina, S., Luo, H. D., Chafeeva, I., Drayton, M., Creagh, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37709-0 · Cited by 30
“Utilization of such concepts lead to the development of polycationic structures that target tumors 60 , lipid nanoparticle-siRNA delivery systems 61,62 ; however, such systems requireanexternaltrigger(chemicalorphysical)inordertoful fi lltheir task.”
Non-Viral Nanoparticle Delivers Small Interfering RNA to Macrophages In Vitro and In Vivo
Zhang, M., Gao, Y., Caja, K. R., Zhao, B., & Kim, J. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118472 · Cited by 30
Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer
Stratford, A. L., Reipas, K. M., Maxwell, C. A., & Dunn, S. E. (2010) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399410001535 · Cited by 30
Astrocyte-targeted siRNA delivery by adenosine-functionalized LNP in mouse TBI model
Xiao, H., Amarsaikhan, O., Zhao, Y., Yu, X., Hu, X., Han, S., Chaolumen, C., & Baigude, H. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102065 · Cited by 29
Harnessing RNAi nanomedicine for precision therapy
Peer, D. (2014) · Molecular and Cellular Therapies · doi:10.1186/2052-8426-2-5 · Cited by 29
“Several RNAi-based clinical trials utilize naked RNAi molecules with local delivery (Table 1), yet, a great promise for the entire RNAi field is based on systemic administration and vast progress has been made using non-human primate models [49,91-95].”
Efficient Transfection of siRNA by Peptide Dendrimer–Lipid Conjugates
Kwok, A., Eggimann, G. A., Heitz, M., Reymond, J., Hollfelder, F., & Darbre, T. (2016) · ChemBioChem · doi:10.1002/cbic.201600485 · Cited by 29
Nanocarriers in Effective Pulmonary Delivery of siRNA: Current Approaches and Challenges
Bardoliwala, D., Patel, V., Javia, A., Ghosh, S., Patel, A., & Misra, A. R. (2019) · Therapeutic Delivery · doi:10.4155/tde-2019-0012 · Cited by 29
Lipid nanoparticles for the inhalation of mRNA
Chang, R. Y. K., & Chan, H. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00794-x · Cited by 29
Hassan, E. M., McWhirter, S., Walker, G. C., Martinez‐Rubi, Y., & Zou, S. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c19311 · Cited by 29
Metadata
- Authors
- Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., Hafez, I. M., Dorkin, J. R., Qin, J., Lam, K., Rajeev, K. G., Wong, K. F., Jeffs, L. B., Nechev, L., Eisenhardt, M. L., Jayaraman, M., Kazem, M., Maier, M. A., Srinivasulu, M., Weinstein, M. J., Chen, Q., Alvarez, R., Barros, S. A., De, S., Klimuk, S. K., Borland, T., Kosovrasti, V., Cantley, W. L., Tam, Y. K., Manoharan, M., Ciufolini, M. A., Tracy, M. A., de Fougerolles, A., MacLachlan, I., Cullis, P. R., Madden, T. D., & Hope, M. J.
- Affiliations
- Arbutus Biopharma (Canada) (CA)
- Alnylam Pharmaceuticals (United States) (US)
- University of British Columbia (CA)
- Corresponding author
- Semple, Sean C
- Akinc, Akin
- ORCID
- Venue
- Nature Biotechnology
- Published
- 2010-01-17
- Volume
- 28
- Issue
- 2
- Pages
- 172-176
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2083249633
- Cited by
- 1,822
- References
- 24
- Citations by year
- 2026: 124 · 2025: 165 · 2024: 175 · 2023: 145 · 2022: 145 · 2021: 119 · 2020: 90 · 2019: 102 · 2018: 83 · 2017: 85 · 2016: 95 · 2015: 85 · 2014: 105 · 2013: 103 · 2012: 98
- FWCI
- 39.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alnylam Pharmaceuticals
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Keywords
- siRNA delivery, lipid nanoparticles, RNAi therapeutics, ionizable cationic lipids
- MeSH terms
- Cations, Drug Carriers, Drug Compounding, Lipids, Transfection, Drug Design, RNA, Small Interfering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
